Durham CRO — RTP Pharma FDA-Precision LinkedIn
Client: Phase II CRO, Durham ($8.4M). Challenge: Generic clinical LinkedIn. Biogen/GSK not engaging clinical operational precision. Programme: FDA Phase I-III methodology content + biostatistics operational vocabulary + Biogen/GSK community Sales Navigator Results (6 months): Biogen connections: +6 | GSK clinical connections: +4 | FDA precision content: 3.6x above generic clinical engagement | CRO evaluation invitations: 4/quarter | Pipeline: $2.0M
